BC
MCID: BRS047
MIFTS: 100

Breast Cancer (BC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 57 12 76 25 75 37 13 55 6 43 3 15 63
Breast Carcinoma 12 25 75 29 55 6 15 73
Breast Cancer, Familial 57 76 53 25 73
Breast Cancer, Lobular 57 38 29 6
Male Breast Cancer 12 53 43 15
Breast Cancer, Susceptibility to 57 29 6
Malignant Neoplasm of Breast 12 25 73
Breast Cancer, Early-Onset 57 29 6
Carcinoma of Male Breast 29 6 73
Mammary Carcinoma 12 75 15
Breast Cancer, Protection Against 57 6
Malignant Neoplasm of Male Breast 12 73
Invasive Ductal Breast Carcinoma 55 73
Breast Cancer, Invasive Ductal 57 38
Hereditary Breast Carcinoma 53 59
Familial Breast Carcinoma 53 59
Familial Cancer of Breast 29 6
Breast Lobular Carcinoma 12 15
Hereditary Breast Cancer 53 59
Familial Breast Cancer 53 59
Neoplasm of the Breast 29 6
Primary Breast Cancer 12 15
Breast Cancer, Male 57 53
Mammary Cancer 12 25
Mammary Tumor 12 55
Breast Cancer, Male, Susceptibility to 57
Primary Malignant Neoplasm of Breast 73
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 57
Breast Cancer, Familial Male 29
Breast Cancer Familial Male 75
Malignant Tumor of Breast 25
Cancer, Breast, Familial 40
Animal Mammary Neoplasms 73
Neoplasm of Male Breast 12
Heritable Breast Cancer 53
Cancer, Breast, Lobular 40
Breast Cancer, Somatic 57
Breast Cancer Familial 75
Breast Neoplasms, Male 44
Male Breast Carcinoma 53
Genetic Breast Cancer 53
Breast Male Carcinoma 55
Breast Cancer in Men 53
Carcinoma of Breast 12
Mammary Neoplasms 73
Mammary Neoplasm 12
Cancer of Breast 25
Breast Neoplasms 44
Cancer, Breast 40
Breast Tumor 12
Bc 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

32
breast cancer:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 114480
ICD10 33 C50 C50-C50
NCIt 50 C9335 C4872
Orphanet 59 ORPHA227535
UMLS via Orphanet 74 C0346153
KEGG 37 H00031
SNOMED-CT via HPO 69 263681008 254838004

Summaries for Breast Cancer

NIH Rare Diseases : 53 Familial breast cancer is a cluster of breast cancer within a family. Most cases of breast cancer occur sporadically in people with little to no family history of the condition. Approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 genes (which are each associated with a unique hereditary cancer syndrome). Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers in some cases. About 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. These clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories.

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to bilateral breast cancer and sporadic breast cancer, and has symptoms including pain, pelvic pain and lameness, animal. An important gene associated with Breast Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Breast cancer and MicroRNAs in cancer. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are breast carcinoma and Decreased viability

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Genetics Home Reference : 25 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

OMIM : 57 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480)

MedlinePlus : 43 Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include Age - the risk rises as you get older Genes - two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes. Personal factors - beginning periods before age 12 or going through menopause after age 55 Other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. Symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. Breast self-exams and mammography can help find breast cancer early, when it is most treatable. One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Men can have breast cancer, too, but it is rare. NIH: National Cancer Institute

CDC : 3 CDC works with partners to reduce the burden of breast cancer in the United States. Learn what CDC is doing.

Novus Biologicals : 56 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

UniProtKB/Swiss-Prot : 75 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

PubMed Health : 63 About breast cancer: Being diagnosed with breast cancer often comes as a shock at first, and makes people feel very frightened and anxious. Having cancer can really turn your life upside down for a while. It helps to know that if you get breast cancer for the first time and it hasn’t spread far, there’s a good chance that treatment can lead to full recovery. There are also many support services that help people in everyday life, to return to work and cope emotionally with breast cancer.

Wikipedia : 76 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1225)
# Related Disease Score Top Affiliating Genes
1 bilateral breast cancer 34.9 RAD51 PALB2 CHEK2 BRCA2 BRCA1 ATM
2 sporadic breast cancer 34.7 TP53 RAD51 ESR1 CHEK2 BRCA2 BRCA1
3 estrogen-receptor positive breast cancer 34.6 TP53 PIK3CA ESR1 AKT1
4 female breast cancer 34.6 TP53 PHB PALB2 ESR1 BRCA2 BRCA1
5 synchronous bilateral breast carcinoma 34.4 TP53 ESR1 BRCA2 BRCA1 ATM
6 glycogen-rich clear cell breast carcinoma 34.2 TP53 ESR1 BRCA2 BRCA1
7 li-fraumeni syndrome 33.4 TP53 CHEK2 BRCA2 BRCA1 ATM
8 adenocarcinoma 33.0 AKT1 CDH1 PIK3CA TP53
9 breast-ovarian cancer, familial 1 32.9 BRCA1 BRCA2
10 li-fraumeni syndrome 2 32.6 CHEK2 TP53
11 ovarian cancer 32.6 TP53 PPM1D PIK3CA PALB2 ESR1 CHEK2
12 ductal carcinoma in situ 32.2 TP53 ESR1 CDH1 BRCA2 BRCA1 AKT1
13 rare adenocarcinoma of the breast 32.2 TP53 SLC22A18 PIK3CA AKT1
14 in situ carcinoma 32.1 TP53 ESR1 CDH1 BRCA1
15 breast medullary carcinoma 32.1 BRCA1 ESR1
16 breast disease 32.1 TP53 ESR1 BRCA2 BRCA1
17 lung cancer 32.0 XRCC3 TP53 SLC22A18 PIK3CA CHEK2 CDH1
18 prostate cancer 31.9 TP53 PIK3CA ESR1 CHEK2 CDH1 CASP8
19 colorectal cancer 31.8 AKT1 BRCA1 BRCA2 BRIP1 CASP8 CDH1
20 breast reconstruction 31.7 BRCA1 BRCA2
21 ataxia-telangiectasia 31.6 ATM BRCA1 CHEK2 TP53
22 endometrial cancer 31.5 TP53 PIK3CA ESR1 CDH1 BRCA2 BRCA1
23 fanconi anemia, complementation group a 31.5 RAD51 PALB2 BRIP1 BRCA2 BRCA1 ATM
24 cowden disease 31.3 PIK3CA BRCA2 BRCA1 AKT1
25 pancreatic cancer 31.3 BRCA1 AKT1 BRCA2 CDH1 PALB2 PIK3CA
26 adamantinoma of long bones 31.3 TP53 PIK3CA ESR1 CDH1 CASP8 BRCA2
27 cervical cancer 31.2 AKT1 CASP8 CDH1 PIK3CA TP53
28 squamous cell carcinoma 31.2 TP53 PIK3CA CHEK2 CDH1 AKT1
29 wilms tumor 1 31.2 TP53 SLC22A18 ESR1 CHEK2 BRCA2
30 breast ductal carcinoma 31.1 TP53 RAD54L ESR1 CDH1 BRCA1
31 esophageal cancer 31.1 TP53 RAD51 PIK3CA CHEK2 CDH1 CASP8
32 ovarian cancer 1 31.0 TP53 PIK3CA CDH1 BRCA2 BRCA1 AKT1
33 adenoid cystic carcinoma 31.0 TP53 PIK3CA CHEK2 CDH1 ATM AKT1
34 xeroderma pigmentosum, variant type 31.0 XRCC3 TP53 RAD54L RAD51 ATM
35 lymphoma, non-hodgkin, familial 31.0 TP53 RAD54L PIK3CA CASP8 ATM
36 breast adenocarcinoma 30.9 TP53 SLC22A18 PIK3CA ESR1 CASP8 AKT1
37 mutagen sensitivity 30.9 XRCC3 TP53 BRCA2 BRCA1
38 nijmegen breakage syndrome 30.9 TP53 CHEK2 BRCA1 ATM
39 breast carcinoma in situ 30.9 TP53 ESR1 BRCA2 BRCA1
40 ovarian disease 30.8 TP53 ESR1 BRCA2 BRCA1 AKT1
41 meningioma, familial 30.8 TP53 ESR1 CDH1 AKT1
42 hereditary breast ovarian cancer syndrome 30.8 TP53 RAD51 PALB2 CHEK2 BRIP1 BRCA2
43 lung cancer susceptibility 3 30.8 TP53 PIK3CA CDH1 CASP8 AKT1
44 endometrial adenocarcinoma 30.8 AKT1 ESR1 TP53
45 cholangiocarcinoma 30.8 AKT1 CDH1 PIK3CA TP53
46 pancreas adenocarcinoma 30.6 TP53 PIK3CA PALB2 CDH1 BRCA2 BRCA1
47 uterine carcinosarcoma 30.6 CDH1 PIK3CA TP53
48 uterine corpus cancer 30.6 TP53 PIK3CA ESR1 BRCA1
49 fallopian tube carcinoma 30.6 TP53 ESR1 BRCA2 BRCA1
50 cystadenocarcinoma 30.6 AKT1 PIK3CA TP53

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
breast carcinoma


Clinical features from OMIM:

114480

Human phenotypes related to Breast Cancer:

32
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 32 HP:0003002

UMLS symptoms related to Breast Cancer:


pain, pelvic pain, lameness, animal

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.76 PIK3CA
2 Decreased viability GR00221-A-1 10.76 AKT1 ESR1 PIK3CA
3 Decreased viability GR00221-A-2 10.76 AKT1 BRCA1 CHEK2 ESR1 PIK3CA
4 Decreased viability GR00221-A-3 10.76 AKT1 BRCA1 CHEK2 ATM
5 Decreased viability GR00221-A-4 10.76 AKT1 CHEK2 ESR1 PIK3CA ATM
6 Decreased viability GR00301-A 10.76 BRCA1
7 Decreased viability GR00342-S-2 10.76 CHEK2
8 Decreased viability GR00402-S-2 10.76 AKT1 BRCA1 CHEK2 ESR1 PIK3CA ATM
9 Decreased homologous recombination repair frequency GR00151-A-1 10.74 BARD1 BRCA1 RAD51
10 Decreased homologous recombination repair frequency GR00151-A-2 10.74 BRCA1 RAD51
11 Decreased homologous recombination repair frequency GR00236-A-1 10.74 BARD1 BRCA1 BRCA2 PALB2 RAD51
12 Decreased homologous recombination repair frequency GR00236-A-2 10.74 ATM BARD1 BRCA1 BRCA2 PALB2 RAD51
13 Decreased homologous recombination repair frequency GR00236-A-3 10.74 BARD1 BRCA1 BRCA2 PALB2 RAD51
14 Decreased viability in esophageal squamous lineage GR00235-A 10.06 BRCA1 BRCA2 CDH1 CHEK2 ESR1 PIK3CA
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.05 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.05 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
17 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.97 ATM BARD1 BRCA1 BRCA2 BRIP1 CASP8
18 Decreased viability with cisplatin GR00101-A-4 9.65 BARD1 BRCA1 BRCA2 BRIP1 RAD51
19 Decreased viability after ionizing radiation GR00232-A-2 9.54 ATM BRCA1 BRCA2
20 Synthetic lethal with cisplatin GR00101-A-1 9.43 BARD1 BRCA1 BRCA2 BRIP1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
2 endocrine/exocrine gland MP:0005379 10.32 AKT1 ATM BRCA1 BRCA2 BRIP1 CASP8
3 growth/size/body region MP:0005378 10.3 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
4 embryo MP:0005380 10.27 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
5 homeostasis/metabolism MP:0005376 10.25 AKT1 ATM BRCA1 BRCA2 BRIP1 CASP8
6 mortality/aging MP:0010768 10.19 AKT1 ATM BARD1 BRCA1 BRCA2 CASP8
7 immune system MP:0005387 10.18 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
8 hematopoietic system MP:0005397 10.17 AKT1 ATM BRCA1 BRCA2 CASP8 CHEK2
9 integument MP:0010771 10.1 AKT1 ATM BRCA1 BRCA2 CASP8 CDH1
10 neoplasm MP:0002006 10.03 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
11 nervous system MP:0003631 9.73 AKT1 ATM BARD1 BRCA1 BRCA2 BRIP1
12 reproductive system MP:0005389 9.4 AKT1 ATM BRCA1 BRCA2 BRIP1 CDH1

Drugs & Therapeutics for Breast Cancer

PubMedHealth treatment related to Breast Cancer: 63

The treatment options always depend on the type and size of the tumor, where it has spread to (if it has spread), the patient’s general health, as well as their personal preferences. Breast cancer can be treated with surgery, radiation and medication. Different treatment approaches are often combined.The standard treatment is to try to surgically remove as much of the tumor as possible. Neighboring lymph nodes are sometimes also removed. If the tumor is small, women are often faced with a decision: Should they keep the breast or have it completely removed? Nowadays many women can have surgery that allows them to keep the breast (breast-conserving surgery). But sometimes the entire breast needs to be removed (mastectomy) to make sure that all of the tumor tissue has gone.Chemotherapy (treatment with medication) is sometimes used to shrink larger tumors before surgery and make it easier to operate on them. This kind of treatment is called “neoadjuvant chemotherapy.”Chemotherapy is sometimes used after surgery too. Women who have a hormone-sensitive tumor may have anti-hormonal therapy. This aims to slow down tumor growth.After breast-conserving surgery the surrounding tissue is exposed to radiation, if possible, so that any remaining tumor cells can be destroyed. This is sometimes necessary after a mastectomy as well. Radiotherapy is also commonly used if the tumor cannot be surgically removed.The different types of treatment can be very difficult to go through and sometimes have very severe side effects or cause other medical problems. The side effects vary depending on the kind of treatment, but they are often easy to treat. The treatment of side effects is part of what is known as supportive care.Before deciding on whether to have a particular treatment, there is usually enough time to get information from your doctor about the possible benefits and the expected side effects, and to talk with your family or other people who are close to you. You have the right to seek a second opinion from another doctor or to decide not to have a treatment.

FDA approved drugs:

(show all 48)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Afinitor 18 49 EVEROLIMUS Novartis March 2009
3
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
4
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
7
CEA-Scan 18 Immunomedics April 1996
8
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
9
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
10
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
11
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
12
Femara 18 49 LETROZOLE Novartis January 2001
13
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
14
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
15
Halaven 18 49 ERIBULIN MESYLATE Eisai November 2010
16
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
17
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
18
Inform HER-2/neu breast cancer test 18 Oncor January 1998
19
Iressa 18 49 GEFITINIB AstraZeneca May 2003
20
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
21
Kadcyla 18 49 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
22
Lupron Depot 18 49 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
23
Miraluma Test 18 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
24
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
25
Neulasta 18 PEGFILGRASTIM Amgen January 2002
26
Neutroval 18 tbo-filgrastim Teva Pharmaceutical August 2012
27
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
28
Perjeta 18 49 PERTUZUMAB Genentech June 2012
29
Premarin 18 ESTROGENS CONJUGATED Wyeth July of 2003
30
Self-examination breast pad 18 Inventive Products on December 22, 1995
31
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
32
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
33
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
34
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
35
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
36
Tykerb 18 49 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
37
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
38
Xeloda 18 49 CAPECITABINE Roche April 1998/ May 2001
39
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
40
Yervoy 18 49 IPILIMUMAB Bristol-Myers Squibb March 2011
41
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
42
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
43
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
44
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
45
Opsumit 18 MACITENTAN Actelion Pharmaceuticals October 2013
46
Remodulin 18 TREPROSTINIL United Therapeutics May 2002
47
Rhinocort Aqua Nasal Spray 18 BUDESONIDE AstraZeneca October 1999
48
Xolair 18 OMALIZUMAB Genentech June 2003

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
2
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118072-93-8 68740
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 439-14-5 3016
6
Methylene blue Approved, Investigational Phase 4,Phase 2,Not Applicable 61-73-4
7
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
8
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
12
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
13
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
14
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
15
Povidone Approved Phase 4,Phase 2 9003-39-8
16
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
17
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
18
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 55-56-1 2713 9552079
19
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
22
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
23
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 6918365 151165
24
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
25
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
27
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
29
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
30
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
31
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
32
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
33
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
34 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
35
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6740-88-1 3821
36
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 329-65-7 838
37
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-43-4 5816
38
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
39
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
40
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
41
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 107868-30-4 60198
42
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
43
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
44
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
45
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10540-29-1 2733526
46
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 180288-69-1 9903
47
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
48
Palbociclib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 571190-30-2 11431660 5330286 5005498
49
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
50
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65807-02-5 47725 5311128

Interventional clinical trials:

(show top 50) (show all 9303)
# Name Status NCT ID Phase Drugs
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
3 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
4 Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer Unknown status NCT02766530 Phase 4
5 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
6 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
7 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
8 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
9 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
10 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
11 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
12 Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer Unknown status NCT02903524 Phase 4 Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;pirarubicin and cyclophosphamide
13 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
14 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
15 Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer Unknown status NCT01849380 Phase 4 S-1;5-FU
16 Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer Unknown status NCT02781259 Phase 4 Indocyanine green
17 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
18 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
19 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
20 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
21 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
22 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
23 Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
24 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
25 Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Unknown status NCT01913990 Phase 4 Dexamethasone, Ondansetron, Aprepitant
26 18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging of the Breast Unknown status NCT01956890 Phase 4 PET
27 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
28 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
29 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
30 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
31 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4 ketalar
32 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
33 Local Anesthetic for Total Mastectomy Surgery Unknown status NCT02893384 Phase 4 Local Anesthetic Injection above the serratus anterior
34 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
35 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
36 Intraoperative Ketamine on Chronic Pain After Mastectomy Unknown status NCT02729805 Phase 4 Saline;Ketamine 0.5mg/kg;Ketamine 0.75mg/kg
37 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
38 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
39 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
40 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
41 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4 Pamidronate;Zoledronic acid;placebo
42 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4 Pamidronate
43 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4 Letrozole
44 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Completed NCT01127295 Phase 4 Tamoxifen, Letrozole, Anastrozole or Exemestane
45 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed NCT00127933 Phase 4 capecitabine [Xeloda];Taxotere;Herceptin (HER2-neu positive patients only);capecitabine [Xeloda];Taxotere
46 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
47 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4 Pegylated liposomal doxorubicin (Caelyx)
48 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Completed NCT01176916 Phase 4 Aromasin (exemestane)
49 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
50 Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients Recruiting NCT03123770 Phase 4 Pegylated liposomal doxorubicin;Cyclophosphamide;Epirubicin;Docetaxel

Search NIH Clinical Center for Breast Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :